FibroGen Inc. said the U.S. Food and Drug Administration granted its pancreatic cancer treatment the fast-track designation.
Pamrevlumab is intended to treat patients with locally advanced unresectable pancreatic cancer, or those whose cancer has spread outside the pancreas and could not be removed entirely through surgery.
The fast track designation follows a review of the phase 2 study evaluating the therapy in combination with chemotherapy medicines gemcitabine and nab-paclitaxel.
"There are no approved treatment options for patients with locally advanced pancreatic cancer, who face a short life expectancy," said Peony Yu, the chief medical officer of the San Francisco-based biopharmaceutical company.
